ProCE Banner Activity

Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine as Frontline Combination Therapy for Advanced-Stage cHL

Slideset Download
Conference Coverage

The combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine achieved a high CR rate at the end of treatment with low incidence of peripheral neuropathy and no episodes of febrile neutropenia.

Released: December 17, 2022

Expiration: December 16, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen